Lifelight has raised over $8 million to date to continue with its bid to turn every device on the planet into a self-monitoring healthcare platform.
Supported by NHS England from the beginning, Lifelight’s vision has also been shared by other healthcare and industry stakeholders in the form of grants and equity funding, including a $1.5 million grant from SBRI Healthcare, an NIHR & NHSX AI in Health Award and multiple grants and loans from Innovate UK.
Significantly $3.5 million alone was raised in the last 14 months during the pandemic. Accelerated by Coronavirus, Lifelight is moving forward with plans to allow clinicians to know a patient’s vital signs remotely, allowing vitals measurements to continue to be taken in real-time with zero contact.
Clinically validated and regulatory approved, and with its ability to measure vital signs simply using the patient’s own smartphone, Lifelight removes the cost and complexity of hardware blood pressure cuffs and pulse oximeters. It can be embedded into existing healthcare platforms and pathways, allowing them to be more efficient, more effective, and more scalable. It enables existing digital health pathways to be revisited, revised, and reengineered.
In development for over five years, from its inception Lifelight has been based at the University of Southampton Business Park, joining the park’s Catalyst programme in 2015 with just three employees. The gave the business a home and the opportunity to learn from fellow entrepreneurs, both on the programme and around the Science Park. Lifelight was also part of the DigitalHealth.London Accelerator programme.
Laurence Pearce, Lifelight’s CEO & founder said: “The next 12 months will be an exciting time in Lifelight’s journey, representing a number of firsts – but as we end the year, we thought it was also important to remember how far we’ve come and thank our many supporters who share in our vision for Lifelight. As well as NHS England, NHSX and an army of study volunteers (thank you!), Portsmouth Hospitals University NHS Trust and Barts Health NHS Trust continue to support our clinical trials, led by Professor Anoop Chauhan MBE and Dr Manish Saxena respectively.
“The company is steadfast on our ethos of delivering solutions to market that adhere to clinical regulation, proven by validation, making Lifelight a unique solution not just across Europe but worldwide.
“Currently a CE Class I medical device, we’re working hard to deliver a CE Class II medical device and gain FDA clearance, allowing greater access to the US and beyond, driven by the need for accessible healthcare for all.”
Lifelight is a technology that allows a smartphone or tablet device to measure blood pressure, pulse, breathing rate, and oxygen saturations by looking into the device's built-in camera for 40 seconds. Completely contactless, with no additional hardware needed, it saves healthcare staff time while improving the patient experience. Lifelight is built to medical grade ISO 13485 and IEC 62304 standards.
